UK Markets closed
NIKKEI 225
27,753.37 -182.25 (-0.65%) HANG SENG
23,788.93 +130.01 (+0.55%) CRUDE OIL
67.48 +0.98 (+1.47%) GOLD FUTURES
1,770.70 +8.00 (+0.45%) DOW
34,639.79 +617.75 (+1.82%) BTC-GBP
42,628.91 -508.07 (-1.18%)
Celldex Therapeutics, Inc. (CLDX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 36.09 |
| Open | 36.34 |
| Bid | 35.40 x 900 |
| Ask | 41.00 x 800 |
| Day's range | 35.48 - 37.96 |
| 52-week range | 15.37 - 57.20 |
| Volume | |
| Avg. volume | 435,756 |
| Market cap | 1.49B |
| Beta (5Y monthly) | 3.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.02 |
| Earnings date | 03 Nov 2021 - 08 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 62.25 |
- Zacks
Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -11.43% and -91.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Investors in Celldex Therapeutics (NASDAQ:CLDX) have made a enviable return of 729% over the past three years
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Mistakes are...
© 2021 Yahoo. All rights reserved.
